Literature DB >> 34815543

Dapagliflozin improves exercise capacity in HFpEF.

Gregory B Lim1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34815543     DOI: 10.1038/s41569-021-00650-0

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.

Authors:  Michael E Nassif; Sheryl L Windsor; Barry A Borlaug; Dalane W Kitzman; Sanjiv J Shah; Fengming Tang; Yevgeniy Khariton; Ali O Malik; Taiyeb Khumri; Guillermo Umpierrez; Sumant Lamba; Kavita Sharma; Sadiya S Khan; Lokesh Chandra; Robert A Gordon; John J Ryan; Sunit-Preet Chaudhry; Susan M Joseph; Chen H Chow; Manreet K Kanwar; Michael Pursley; Elias S Siraj; Gregory D Lewis; Barry S Clemson; Michael Fong; Mikhail N Kosiborod
Journal:  Nat Med       Date:  2021-10-28       Impact factor: 53.440

  1 in total
  1 in total

1.  Current Management of Heart Failure with Preserved Ejection Fraction.

Authors:  Akash H Patel; Balaji Natarajan; Ramdas G Pai
Journal:  Int J Angiol       Date:  2022-09-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.